Reports from UFAG Laboratorien AG rest on a verified institutional identity.
The company is registered in the Swiss Commercial Register under CHE-102.242.879 since 19 December 1997, with a confirmed address at Kornfeldstrasse 4, 6210 Sursee. Named leadership includes Managing Director Dr. Martin Knauf, Olivier Christen, Markus Hämmerli, and Christian Consoni.
The laboratory operates as a B2B contract laboratory for the pharmaceutical and biopharmaceutical industry, offering chemical and microbiological quality testing of pharmaceutical raw materials and analytics of small molecules and biomolecules such as oligonucleotides and monoclonal antibodies.
It provides an online report-verification portal at ufag-laboratorien.ch/verify, which constitutes an offered governance mechanism, though the directory could not confirm a real report through it.
UFAG claims ISO/IEC 17025 accreditation, but no entry in an accreditation body's register was cited, leaving the claim neither verified nor refuted.
The public-evidence reason UFAG holds 'Listed' rather than 'Substantiated' is the absence of an evidenced peptide or research-chemical testing offering. The laboratory's published methods center on pharmaceutical raw-material quality and biomolecule analytics, and no public signal documents a dedicated peptide-testing service. This is distinct from neutral limits on how far this review can go.
Current independent evidence of analytical performance for a specific method and matrix was not found in the source set, and verified competence for peptide-specific methods could not be assessed. No community endorsements, complaints, or discussions referencing UFAG appear in the supplied Reddit and forum material, and no peer-reviewed study or independent press investigation of its analytical performance was found.
No public pricing is available; orders and prices are handled upon request. No concrete open concern was identified in the public signals. These are signals, not a verdict.